Etoposide and Idarubicin in a Modified CHOP-Like Regimen (VICED) for Aggressive Non-Hodgkin's Lymphomas

References

• Fisher R. I., Gaynor E. R., Dahlberg S., Oken M. M., Grogan T. M., Mize E. M., Glick J. H., Coltman C. A., Miller T. P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New Engl. J. Med. 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• McKelvey E. M., Gottlieb J. A., Wilson H. E., Haul A., Talley R. W., Stephens R., Lane M., Gamble J. F., Jones S. E., Grozea P. N., Gutterman J., Coltman C., Moon T. E. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1490
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications on non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Carbone P. P., Kaplan M. S., Musshoff K., Smothers D. W., Tubiana M. Report of the commettee on Hodgkin's disease staging classification. Cancer Res. 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Ass. 1958; 53: 457–481
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemoter Rep. 1966; 50: 163–170
   PubMedGoogle Scholar
• O'Reilly S. E., Klimo P., Connors J. M. The evolving role of etoposide in the management of lymphomas and Hodgkin's disease. Cancer 1991; 67(Suppl. 1)271–280
   PubMed Web of Science ®Google Scholar
• Bellesi G., Rigacci L., Alterini R., Bernards F., Stefanacci S., Innocenti F., Fusco I., Longo G., Di Lollo S., Rossi Ferrini P. A new protocol (MiCEP) for the treatment of intermediate or high-grade non Hodgkin's lymphoma in the elderly. Leukemia & Lymphoma 1996; 20: 475–480
   PubMed Web of Science ®Google Scholar
• Martelli M., Guglielmi C., Coluzzi S., Avvisati G., Amadori S., Giovannini M., Torromeo C., Mandelli F. P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin. Oncol 1993; 11: 2362–2369
   PubMed Web of Science ®Google Scholar
• Zinzani P. L., Bendandi M., Gherlinzoni F., Mazza P., Salvucci M., Aitini E., Miggiano M. C., Gozzetti A., Tura S. VNCOP-B regimen in the treatment of high-grade non-Hodgkin's lymphoma in the elderly. Haematologica 1993; 78: 378–382
   PubMed Web of Science ®Google Scholar
• Bertini M., Freilone R., Vitolo U., Botto B., Ciotti R., Cinieri S., Di Nota A., Di Vito F., Levis A., Orsucci L., Pini M., Rota-Scalabrini D., Todeschini G., Resegotti L. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas feasibility and efficacy of an intensive multidrug regimen. Leukemia and lymphoma 1996; 22: 483–493
   PubMed Web of Science ®Google Scholar
• Caracciolo F., Petrini M., Capochiani E., Papineschi F., Carulli G., Grassi B. Alternating chemotherapy regimen (P-VABEC) for intermediate and high-grade non-Hodgkin's lymphoma of the middle aged and elderly. Hematological Oncology 1994; 12: 185–192
   PubMed Web of Science ®Google Scholar
• Hansen M. M., Bloomfield C. D., JØRgensen J., ErsbØLl J., Pedersen-Bjergaard J., Bloom J., Nissen N. I. VP-16–213 in combination with cyclophosphamide, doxorubicine, vincristine and prednisone in the treatment of non-Hodgkin's lymphomas. Cancer Treat. Rep. 1980; 64: 1135–1139
   PubMedGoogle Scholar
• Koppler H., PflÜGer K. H., Eschenbach I., Pfab R., Lennert K., Wellens W., Schmidt M., Gassel W. D., Kolb T., Häßler R., Schumaker K., v. Speth G., Holle R., Havemann K. CHOP-VP 16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphomas: a phase II multicentric study. Brit. J. Cancer 1989; 60: 79–82
   PubMed Web of Science ®Google Scholar
• Joel S. P., Slevin M. L. Schedule-dependent topoisomerase II-inhibiting drugs. Cancer Chemother. Pharmacol. 1994; 34(Suppl.)S84–88
   PubMed Web of Science ®Google Scholar
• Whitlock J. A., Greer J. P., Lukens J. N. Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia. Cancer 1991; 68: 600–604
   PubMed Web of Science ®Google Scholar
• Ratain M. J., Kaminer L. S., Bitran J. D., Larson R. A., Le Beau M. M., Skosey C., Purl S., Hoffman C., Wade J., Vardiman J. W., Daly K., Rowley J. D., Golomb H. M. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 1987; 70: 1412–1417
   PubMed Web of Science ®Google Scholar
• Pui C. H., Ribeiro R. C., Hancock M. L., Rivera G. K., Evans W. E., Raimondi S. C., Head D. R., Behm F. G., Mahmoud M. H., Sandlund J. T., Crist W. M. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. New Engl. J. Med. 1991; 325: 1682–1687
   PubMed Web of Science ®Google Scholar
• Pollicardo N., O'Brien S., Estey E. H., Al-Bitar M., Pierce S., Keating M., Kantarjian H. M. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution. Leukemia 1995; 10: 27–31
   Web of Science ®Google Scholar
• Kanakura Y., Yonezawa T., Hamaguchi Y., Otsuka A., Matayoshi Y., Kondoh H., Tamaki T., Katagiri S., Kanayama Y., Nishiura T., Aozasa K., Tarui S. Acute promyelocytic leukemia with an intracerebral mass and meningeal involvement after treatment of non-Hodgkin's lymphoma. Cancer 1987; 59: 94–98
   PubMed Web of Science ®Google Scholar
• Raiker A., Green W., Shabaik A., Perlin E. Acute promyelocytic leukemia following treatment of non-Hodgkin's lymphoma. Cancer 1989; 63: 1402–1406
   PubMed Web of Science ®Google Scholar
• Haupt R., Comelli A., Rosanda C., Sessarego M., De Bernardi B. Acute myeloid leukemia after single-agent treatment with etoposide for Langherans' cell histiocytosis of bone. Am. J. Ped. Hematol. Oncol. 1993; 15: 255–257
   PubMedGoogle Scholar
• Horibe K., Matsushita T., Numata S., Miyajima Y., Katayama I., Kitabayashi T., Yanai M., Sekiguchi N., Egi S. Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for Langherans cell histiocytosis. Cancer 1993; 72: 3723–3726
   PubMed Web of Science ®Google Scholar
• Lopez-Andreu J. A., Ferris J., Verdeguer A., Esquembre C., Senent M., Castel V. Secondary acute promyelocytic leukemia in a child treated with epipodophyllotoxins. Am. J. Ped. Hematol. Oncol. 1994; 16: 384–386
   PubMedGoogle Scholar
• Matsuzaki A., Inamitsu T., Watanabe T., Ohga S., Ishii E., Nagotoshi Y., Tasaka H., Suda M., Ueda K. Acute promyelocytic leukemia in a patient treated with etoposide for Langherans cell histiocytosis. Brit. J. Haematol. 1994; 86: 887–889
   PubMed Web of Science ®Google Scholar
• Bhavnani M., Wolstenholme R. J. Razoxane and acute promyelocytic leukaemia. Lancet 1987; ii: 1085
   Google Scholar
• Coonley C. J., Warrel R. P., Jn., Straus D. J., Young C. W. Clinical evaluation of 4-demethoxydaunorubicin in patients with advanced malignant lymphoma. Cancer Treatm. Rep. 1983; 67: 949–950
   PubMedGoogle Scholar
• Gillies H., Liang R., Rogers H., Harper P., Parapia L., Cox G., Johnson S. Phase II trial of idarubicin in patients with advanced lymphomas. Cancer Chemother. Pharmacol. 1988; 21: 261–264
   PubMed Web of Science ®Google Scholar
• Case D. C., Gerber M. C., Gams R. A., Crawford J., Votaw M. L., Higano C. S., Pruitt B. T., Gould J. Phase II study of intravenous idarubicin in unfavourable non-Hodgkin's lymphoma. Leukemia & Lymphoma 1989; 10: 73–79
   Google Scholar
• Brugiatelli M., Federico M., Gobbi P. G., Avanzini P., Callea V., Cavanna L., De Pasquale A., Di Prisco U., Di Rienzo N., Silingardi V., Mauri C. Epidoxorubicin vs idarubicin containing regimens in intermediate and high grade non-Hodgkin's lymphoma: preliminary results of a multicentric randomized trial. Haematologica 1993; 78: 306–312
   PubMedGoogle Scholar
• Zinzani P. L., Martelli M., Storti S., Musso M., Cantonetti M., Leone G., Cajozzo A., Papa G., Iannitto E., Perrotti A., Bendandi M., Gherlinzoni F., Gentilini P., Rossi G., Aitini E., Mandelli F., Tura S. Phase III comparative trial using CHOP versus CIOP in the treatment of advanced intermediate grade non-Hodgkin's lymphoma. Leukemia & Lymphoma 1995; 19: 329–335
   PubMed Web of Science ®Google Scholar
• Michieli M., Michelutti A., Damiani D., Pipan C., Raspadori D., Lauria F., Baccarani M. A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives. Leukemia & Lymphoma 1993; 9: 255–264
   PubMed Web of Science ®Google Scholar
• Reid J. M., Pendergrass T. W., Krailo M. D., Hammond G. D., Ames M. M. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Children Cancer Study Group report. Cancer Research 1990; 50: 6525–6528
   PubMed Web of Science ®Google Scholar
• Casazza A. M., Bertazzoli C., Pratesi G., Bellini O., Di Marco A. Antileukemic activity and cardiac toxicity of 4-demethoxydauno-rubicin (4-DMDR) in mice. Proc. Am. Assoc. Cancer Res. 1979; 20: 16
   Web of Science ®Google Scholar
• Bruno A., Cavallo-Perin P., Cassader M., Pagano G. Deflazacort vs prednisone. Effect on blood glucose control in insulin-treated diabetics. Arch. Intern. Med. 1987; 147: 679–680
   PubMed Web of Science ®Google Scholar
• Loftus J., Allen R., Hesp R., David J., Reid D. M., Wright D. J., Green J. R., Reeve J., Ansell B. M., Woo P. M. Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: a relatively bone-sparing effect of deflazacort. Pediatrics 1991; 88: 428–436
   PubMed Web of Science ®Google Scholar